Zein Obagi, M.D., Receives JDD Leaders of Distinction Award

Published January 26, 2014

Zein Obagi, M.D., Receives JDD Leaders of Distinction Award
IRVINE, Calif., Jan. 21, 2014 /PRNewswire/ — ZO Skin Health, Inc. is especially pleased to announce that internationally renowned dermatologist Zein Obagi, M.D., is a recipient of the prestigious Journal of Drugs in Dermatology (JDD) Leaders of …
Read more on SYS-CON Media (press release)

Glaucoma: The 'Silent Thief' Begins to Tell its Secrets
As we develop a better understanding of the disease process, we hope this will lead to new, more effective treatments and possibly even preventive therapies for it," said Hemin Chin, Ph.D., director of the Glaucoma and Optic Neuropathies program at the …
Read more on Indian Country Today Media Network

Intercept Pharmaceuticals Inc (ICPT): Why It Could Pay Off To Look At The Big …
The decision to prematurely cease the trial stemmed from Intercept's lead drug, obeticholic acid ("OCA"), superiorly met its primary outcome needed for the treatment of non-alcoholic steatohepatitis ("NASH"). Since their ascension, ICPT shares traded …
Read more on Seeking Alpha

Tivicay (Dolutegravir) Is Approved in Europe
Already approved by the U.S. Food and Drug Administration (FDA), Tivicay was studied in both treatment-experienced and treatment-naive people with HIV, including those with resistance to another integrase inhibitor, Isentress (raltegravir). The …
Read more on AIDSmeds.com HIV/AIDS Treatment News

Drug Treatment for Atrial Fibrillation: Mikhael El Chami, MD —